News Releases

SAN RAMON, Calif., Oct. 27, 2017 /PRNewswire/ -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced that the Revivent TC™ TransCatheter Ventricular Enhancement System will be featured during the presentation of a Revivent TC procedure at the 29^th Transcatheter Cardiovascular Therapeutics (TCT), in Denver, Colorado. Prof. Andrew Wechsler, cardiothoracic surgeon, will present the procedure on Monday, October 30^th.

Other BioVentrix events at TCT include the presentation of long-term clinical outcomes by Prof. Christoph Schmitz, Ludwig Maximilian University, Munich, Germany on Monday, October 30^th. Additionally, Dr. Patrick Klein will present the preliminary clinical outcomes at the St. Antonius Hospital in Nieuwegein, Netherlands on Wednesday, November 1^st.

"BioVentrix continues to gain adoption with the Revivent TC system for treating post-MI, ischemic cardiomyopathy patients. We have commercialized the system in Europe and Asia. Over the past few months we have commenced patient enrollment in the FDA-approved ALIVE pivotal clinical trial. The BioVentrix presentations at TCT offer a comprehensive view of the LIVE™ procedure and the positive short- and long-term clinical outcomes of the Revivent TC system," said Mr. Kenneth Miller, President and CEO of BioVentrix, Inc.

TCT PRESENTATION SCHEDULE (listed chronologically)

Monday, October 30^th

• Long-term Sustained Reduction of Heart Failure Symptoms through Less-Invasive Ventricular Reshaping: Prof. Christoph Schmitz, M.D., will present at 9:54 a.m. in the Moderated Posters 6 area, Exhibit Hall, Exhibit Level, TCT Number 140.
  
  
• Transcatheter Left Ventricular Reconstruction for Treatment of Post-Myocardial Infarction Ischemic Cardiomyopathy: Prof. Andrew Wechlser, M.D., will present at 4:00 p.m. during the Edited Taped Cases session in the Presentation Theater 4, Exhibit Hall, Exhibit Level.
  

Wednesday, November 1^st

• Epicardial Catheter-based Ventricular Restoration in Ischemic HF patients with Antero-septal Scar: Prof. Yan Wang, M.D., will present at 10:45 a.m. during the TCT Challenging Cases session in Lobby C, Meeting Room Level, TCT Number 1596.
  
  
• Preliminary Results of Hybrid, Less-Invasive Left Ventricular Reshaping for Ischemic Cardiomyopathy – the St. Antonius Hospital Experience: Dr. Patrick Klein, M.D., will present at 12:02 p.m. during the Interventional Heart Failure and Structural Heart Interventions session in the Mile High Ballroom 2A-3A, Ballroom Level.
  

All presentations are listed in Mountain Daylight Time and will take place at the Colorado Convention Center.

About BioVentrix and the Revivent TC System

BioVentrix, a privately held medical technology company headquartered in San Ramon, Calif., is focused on developing and commercializing minimally invasive therapies for treating HF.  The company has received CE mark certification for the Revivent TC TransCatheter Ventricular Enhancement System: a hybrid closed-chest procedure to treat patients suffering from heart failure symptoms related to cardiomyopathy. BioVentrix is currently enrolling patients in the ALIVE pivotal clinical trial. The trial is designed to demonstrate the safety and effectiveness of the Revivent TC™ TransCatheter Ventricular Enhancement System. The ALIVE trial plans to enroll 120 patients at up to 20 sites in the U.S. and U.K. with a primary endpoint analysis at 1 year. Placement of the Revivent TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled towards one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by as much as 30-40 percent¹.

Click here for corporate video with animation

Note: The Revivent TC System is approved for sale in Europe; it is not approved for sale in the United States.

¹Wechsler, A. et al., Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna, Austria.

SOURCE BioVentrix, Inc.